Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines
Jordi Codony‐Servat(Breast Cancer Research Foundation), Rafael Rosell(Instituto Oncológico Dr. Rosell)
Cited by 17
Related Papers
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
|Nature Communications|2017|182
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
|Molecular Cancer Therapeutics|2006|107
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
|British Journal of Cancer|2017|76
Liquid Biopsy in Non-Small Cell Lung Cancer
|Frontiers in Medicine|2016|66